Showing results (151-160 of 389) with videos related to

Sort By:
Pageof 39
Oncology and Therapy|June 8, 2023
Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in VietnamDuc Thanh Le, Lap Thanh Bui, Chu Van Nguyen, et al.
Oncology and Therapy|September 7, 2020
An Overview of Current Recommendations and Options for the Management of Cancer Pain: A Comprehensive ReviewKyle L Gress, Karina Charipova, Alan D Kaye, et al.
Oncology and Therapy|August 29, 2020
Information Needs of Black Prostate Cancer Patients Receiving Treatment Within the South African Public Healthcare SystemMelissa Taljaard, Germaine T Lovric, Aviwe M Makenzi, et al.
Oncology and Therapy|December 18, 2020
The Totality of Evidence and Use of ABP 215, a Biosimilar to BevacizumabJerome Goldschmidt, Vladimir Hanes
Oncology and Therapy|April 28, 2021
Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World DataJerzy E Tyczynski, Ravi Potluri, Ryan Kilpatrick, et al.
Oncology and Therapy|August 18, 2022
Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon CancerHassan Ehteram, Fatemeh Aslanbeigi, Ebrahim Ghoochani Khorasani, et al.
Oncology and Therapy|December 15, 2025
Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast)Rick Bangs, Roger Li
Oncology and Therapy|December 6, 2025
The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A PodcastPeter Whelan, Kirsty Balachandran, Kenrick Ng
Oncology and Therapy|November 4, 2025
Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-AnalysisCora N Sternberg, Patrick Squires, Yan Song, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Pageof 39